Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590036 | 1.00 | PNMT (0.67) | PNMTADRA2A | |
| SCHEMBL894205 | 1.00 | PNMT (0.67) | PNMTADRA2A | |
| SCHEMBL29570471 | 1.00 | PNMT (0.67) | PNMTADRA2A | |
| SCHEMBL29743356 | 1.00 | PNMT (0.67) | PNMTADRA2A | |
| SCHEMBL894207 | 1.00 | PNMT (0.67) | PNMTADRA2A | |
| Hydrochloric Acid SCHEMBL7478887 | 0.98 | PNMT (0.65) | PNMTADRA2A | |
| Hydrochloric Acid SCHEMBL7478882 | 0.98 | PNMT (0.65) | PNMTADRA2A | |
| SCHEMBL8783405 | 0.85 | PNMT (0.64) | PNMT | |
| SCHEMBL11388285 | 0.85 | PNMT (0.64) | PNMT | |
| SCHEMBL8853554 | 0.83 | PNMT (0.71) | PNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043424-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4308092-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20220306625-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | EIL THERAPEUTICS INC (US) | 2022-09-29 | — | — | US | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3024833-B1 | NOVEL INDOLIZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2017-09-06 | — | — | EP | disclosed |
| US-20160176848-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-06-23 | — | — | US | disclosed |
| WO-2008072850-A1 | TRIAZINE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST ACETYL-COA CARBOXYLASE | AMOREPACIFIC CORPORATION (KR) | 2008-06-19 | — | — | WO | disclosed |
| EP-1149079-B1 | TETRAHYDRO ISOQUINO LINEALKANOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SK CORP (KR) | 2004-04-21 | — | — | EP | disclosed |
| EP-1149079-A1 | TETRAHYDRO ISOQUINO LINEALKANOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SK Corporation (KR) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000046204-A1 | TETRAHYDRO ISOQUINO LINEALKANOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SK CORPORATION (KR) | 2000-08-10 | — | — | WO | disclosed |
| US-5955471-A | USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, INCLUDING DEPRESSION | SK CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0713880-B1 | Stereoselective reduction of 17-ketosteroids | JENAPHARM GMBH (DE) | 1998-06-10 | — | — | EP | disclosed |
| EP-0713880-A2 | Stereoselective reduction of 17-ketosteroids | JENAPHARM GmbH (DE) | 1996-05-29 | — | — | EP | disclosed |
| US-4064247-A | ANALGESIC, ANTIPYRETIC | RHONE-POULENC INDUSTRIES (FR) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | PNMT 2819/4885ADRA2A 3899/4885 |
| US-20220306625-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | BCL2, BCL2A1, BCL2L1 | PNMT 2819/4885ADRA2A 3899/4885 |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PNMT 3623/4885ADRA2A 1445/4885 |
| US-20160176848-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDO1, API5, IDO2 | PNMT 1930/4885ADRA2A 616/4885 |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | MSH2, PMS2, MSH6 | PNMT 1030/4885ADRA2A 3781/4885 |
| US-20240043424-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | BCL2, BCL2A1, BCL2L1 | PNMT 2819/4885ADRA2A 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.